Chondrosarcoma - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Chondrosarcoma - Pipeline Review, H1 2016', provides an overview of the Chondrosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chondrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Chondrosarcoma - The report reviews pipeline therapeutics for Chondrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chondrosarcoma therapeutics and enlists all their major and minor projects - The report assesses Chondrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chondrosarcoma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chondrosarcoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chondrosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Chondrosarcoma Overview 6 Therapeutics Development 7 Pipeline Products for Chondrosarcoma - Overview 7 Pipeline Products for Chondrosarcoma - Comparative Analysis 8 Chondrosarcoma - Therapeutics under Development by Companies 9 Chondrosarcoma - Therapeutics under Investigation by Universities/Institutes 10 Chondrosarcoma - Pipeline Products Glance 11 Clinical Stage Products 11 Chondrosarcoma - Products under Development by Companies 12 Chondrosarcoma - Products under Investigation by Universities/Institutes 13 Chondrosarcoma - Companies Involved in Therapeutics Development 14 Agios Pharmaceuticals, Inc. 14 Celgene Corporation 15 CytRx Corporation 16 EpiZyme, Inc. 17 Horizon Pharma Plc 18 Karyopharm Therapeutics, Inc. 19 Merck & Co., Inc. 20 Novartis AG 21 Chondrosarcoma - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 AG-120 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 aldoxorubicin hydrochloride - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 CC-90007 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 interferon gamma-1b - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 pazopanib hydrochloride - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 pembrolizumab - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 selinexor - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 tazemetostat - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Chondrosarcoma - Recent Pipeline Updates 70 Chondrosarcoma - Dormant Projects 130 Chondrosarcoma - Discontinued Products 131 Chondrosarcoma - Product Development Milestones 132 Featured News & Press Releases 132 May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 132 Appendix 134 Methodology 134 Coverage 134 Secondary Research 134 Primary Research 134 Expert Panel Validation 134 Contact Us 134 Disclaimer 135
List of Tables
Number of Products under Development for Chondrosarcoma, H1 2016 7 Number of Products under Development for Chondrosarcoma - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Chondrosarcoma - Pipeline by Agios Pharmaceuticals, Inc., H1 2016 14 Chondrosarcoma - Pipeline by Celgene Corporation, H1 2016 15 Chondrosarcoma - Pipeline by CytRx Corporation, H1 2016 16 Chondrosarcoma - Pipeline by EpiZyme, Inc., H1 2016 17 Chondrosarcoma - Pipeline by Horizon Pharma Plc, H1 2016 18 Chondrosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 19 Chondrosarcoma - Pipeline by Merck & Co., Inc., H1 2016 20 Chondrosarcoma - Pipeline by Novartis AG, H1 2016 21 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Stage and Target, H1 2016 24 Number of Products by Stage and Mechanism of Action, H1 2016 26 Number of Products by Stage and Route of Administration, H1 2016 28 Number of Products by Stage and Molecule Type, H1 2016 30 Chondrosarcoma Therapeutics - Recent Pipeline Updates, H1 2016 70 Chondrosarcoma - Dormant Projects, H1 2016 130 Chondrosarcoma - Discontinued Products, H1 2016 131
List of Figures
Number of Products under Development for Chondrosarcoma, H1 2016 7 Number of Products under Development for Chondrosarcoma - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Top 10 Targets, H1 2016 23 Number of Products by Stage and Top 10 Targets, H1 2016 23 Number of Products by Top 10 Mechanism of Actions, H1 2016 25 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 25 Number of Products by Routes of Administration, H1 2016 27 Number of Products by Stage and Routes of Administration, H1 2016 27 Number of Products by Molecule Types, H1 2016 29 Number of Products by Stage and Molecule Types, H1 2016 29
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.